These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

126 related articles for article (PubMed ID: 1728834)

  • 1. Clinical and basic aspects of an anorexiant, mazindol, as an antiobesity agent in Japan.
    Inoue S; Egawa M; Satoh S; Saito M; Suzuki H; Kumahara Y; Abe M; Kumagai A; Goto Y; Shizume K
    Am J Clin Nutr; 1992 Jan; 55(1 Suppl):199S-202S. PubMed ID: 1728834
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical studies with mazindol.
    Inoue S
    Obes Res; 1995 Nov; 3 Suppl 4():549S-552S. PubMed ID: 8697057
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Short-term and long-term clinical evaluation of a non-amphetaminic anorexiant (mazindol) in the treatment of obesity.
    Enzi G; Baritussio A; Marchiori E; Crepaldi G
    J Int Med Res; 1976; 4(5):305-18. PubMed ID: 1028632
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of the non-amphetaminergic anorexiant, mazindol, on neuronal activity and hypothalamic control of gastric acid secretion in rats.
    Shiraishi T
    Int J Obes; 1985; 9(4):285-97. PubMed ID: 3905642
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Double-blind evaluation of mazindol in refractory obesity.
    Smith RG; Innes JA; Munro JF
    Br Med J; 1975 Aug; 3(5978):284. PubMed ID: 1097046
    [No Abstract]   [Full Text] [Related]  

  • 6. AN 448 Sandoz (Mazindol) in the treatment of obesity.
    Wallace AG
    Med J Aust; 1976 Mar; 1(11):343-5. PubMed ID: 775265
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Effect of mazindol on obesity induced by administration of gold thioglucose].
    Ohminami K; Matsuoka E; Takahashi Y; Shimizu D; Okuda H
    Nihon Yakurigaku Zasshi; 1984 Feb; 83(2):123-32. PubMed ID: 6430760
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Mazindol: its efficacy and mode of action in generating weight loss.
    Johnson WG; Hughes JR
    Addict Behav; 1979; 4(3):237-44. PubMed ID: 495247
    [No Abstract]   [Full Text] [Related]  

  • 9. Double blind cross-over study of a new appetite suppressant AN 448.
    Haugen HN
    Eur J Clin Pharmacol; 1975; 8(1):71-4. PubMed ID: 786676
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Effects of an anorexiant, mazindol, on metabolic abnormalities of rats with ventromedial hypothalamic lesions].
    Inoue S; Egawa M; Satoh S
    Nihon Yakurigaku Zasshi; 1984 May; 83(5):441-9. PubMed ID: 6469133
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Mazindol effects on the salivary and gastric acid secretory mechanisms].
    Shiraishi T
    Nihon Yakurigaku Zasshi; 1984 Feb; 83(2):159-72. PubMed ID: 6745806
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Double blind clinical trial of mazindol on weight loss blood glucose, plasma insulin and serum lipids in overweight diabetic patients.
    Slama G; Selmi A; Hautecouverture M; Tchobroutsky G
    Diabete Metab; 1978 Sep; 4(3):193-9. PubMed ID: 361463
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Slowed gastric evacuation accounts for the reduction of food intake by anorectic drugs.
    Jonderko K; Kucio C; Skrzypek D
    Eur J Clin Nutr; 1988 Jul; 42(7):627-31. PubMed ID: 3066620
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of anorexiant drugs on growth hormone secretion in obese children.
    Baritussio A; Enzi G; Rigon G; Molinari M; Inelmen EM; Crepaldi G
    Pharmacol Res Commun; 1978 Jun; 10(6):529-40. PubMed ID: 693565
    [No Abstract]   [Full Text] [Related]  

  • 15. A comparison of mazindol (Teronac) with diethylpropion in the treatment of exogenous obesity.
    Murphy JE; Donald JF; Molla AL; Crowder D
    J Int Med Res; 1975; 3(3):202-6. PubMed ID: 162676
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A double-blind trial of mazindol using a very low calorie formula diet.
    Baird IM; Howard AN
    Int J Obes; 1977; 1(3):271-8. PubMed ID: 363631
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Anorexiant drugs in the ambulant treatment of obese patients (author's transl)].
    Jenny S; Zimmermann KG; Radielovic P; Bühlmann AA
    Schweiz Rundsch Med Prax; 1976 Jul; 65(28):874-8. PubMed ID: 1005298
    [No Abstract]   [Full Text] [Related]  

  • 18. Usefulness of mazindol in combined diet therapy consisting of a low-calorie diet and Optifast in severely obese women.
    Yoshida T; Sakane N; Umekawa T; Yoshioka K; Kondo M; Wakabayashi Y
    Int J Clin Pharmacol Res; 1994; 14(4):125-32. PubMed ID: 7607785
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A multicentre study comparing mazindol and placebo in obese patients.
    Walker BR; Ballard IM; Gold JA
    J Int Med Res; 1977; 5(2):85-90. PubMed ID: 326596
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Drug therapy in obesity].
    Ishii J
    Nihon Rinsho; 1988 Nov; 46(11):2491-6. PubMed ID: 3241376
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.